FDA Approves Omeros' YARTEMLEA(R) -- First and Only Therapy Indicated for TA-TMA

Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET -- -- First and only approved option: YARTEMLEA(R) is the only approved treatment for hematopoietic stem cell ...

Omeros: Stock Pops On Yartemlea Approval, Longer-Term Upside Likely

Omeros (OMER) receives FDA approval for Yartemlea (narsoplimab) in TA-TMA, driving shares up nearly 80% to a $1bn+ valuation.
Tax Guru

Penalty Quashed for Lack of Knowledge in Misuse of Signed Export Documents

CESTAT Chennai held that penalties cannot be imposed when there is no evidence that the CHA manager knowingly aided mis-declaration or ineligible drawback ...
Le Lézard

FDA Approves Omeros' YARTEMLEA® ? First and Only Therapy Indicated for TA-TMA

Omeros Corporation today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA® (narsoplimab-wuug) for the treatment of hematopoietic stem cell transplant-associated ...
Tax Guru

Customs Adjudication Not Invalid Merely for Non-Communication of Time Extension: Delhi HC

HC held that Section 28 of Customs Act does not mandate communication of an extension order for adjudication. Delayed ...
The Norman Transcript

Norman mother details husbands detainment by Immigration and Customs Enforcement

A Norman mother is fighting to get her husband released from a detention center in Texas after he was detained by Immigration ...
BMJ Open

Clinical characteristics and outcomes of patients with type 2 diabetes mellitus and chronic kidney disease from two new-user medication cohorts: a retrospective cohort study ...

Objectives Given the rapidly evolving therapeutic landscape for type 2 diabetes (T2D) and chronic kidney disease (CKD), this study aimed to characterise the clinical profiles and real-world outcomes ...